Business Context and Reporting Period
This Form 8-K Current Report from cbdMD, Inc. (NYSE American: YCBD) covers events occurring on March 30, 2026, specifically the results of the Company's 2026 Annual Meeting of Shareholders and the subsequent approval of the 2025 Equity Compensation Plan.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it details significant capital structure actions approved by shareholders:
- Equity Compensation Plan: The 2025 Plan reserves 891,316 shares for issuance. It includes an "evergreen" provision to automatically increase available shares by 2% of outstanding stock annually (up to 300,000 shares) starting October 1, 2026.
- Executive Compensation: CEO and CFO T. Ronan Kennedy received a restricted stock award of 445,000 shares, contingent on the Plan's approval.
- Share Count: There were 10,495,561 shares of common stock outstanding and entitled to vote at the meeting.
- Attendance: 5,732,044 shares (54.6%) were represented, constituting a quorum.
Material Changes and Shareholder Votes
Shareholders approved seven key proposals at the 2026 Annual Meeting, resulting in the following material changes:
- Reverse Stock Split Authorization: Shareholders approved an amendment to the articles of incorporation allowing the Board to effect a reverse stock split at a ratio between 1:2 and 1:10 within one year of the meeting.
- Waiver of Exchange Caps (Dilution Risk): Proposals 4, 5, and 6 approved the issuance of shares upon conversion of Series B and Series C Convertible Preferred Stock and under an Equity Line of Credit (ELOC) with C/M Capital Master Fund, LP. These issuances may exceed the 20% exchange cap, potentially resulting in significant dilution to existing shareholders.
- Director Elections: All seven director nominees were elected, including T. Ronan Kennedy and Jeffrey Porter, who received the highest "For" votes.
- Auditor Ratification: Cherry Bekaert LLP was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance or management commentary regarding future revenue or earnings. Key risks and contingencies identified include:
- Dilution: Explicit acknowledgment that the conversion of preferred stock and the ELOC agreement may result in the issuance of more than 20% of outstanding common stock, causing significant dilution.
- Stock Price Volatility: The authorization of a reverse stock split suggests management is considering actions to adjust the share price, which may impact liquidity and market perception.
- Executive Retention: The issuance of 445,000 shares to the CEO/CFO is tied to the 2025 Plan, linking executive retention to the success of the equity program.
Investor Verification Checklist
- Verify the exact reverse stock split ratio if and when the Board exercises the authority granted in Proposal 3.
- Monitor the conversion rates and timing for Series B and Series C Preferred Stock to assess the actual dilution impact.
- Review the terms of the ELOC agreement with C/M Capital Master Fund, LP, to understand the potential volume of shares that may be sold.
- Confirm the vesting schedule for the 445,000 shares granted to T. Ronan Kennedy.
- Check subsequent filings for the updated share count following any conversions or ELOC draws.